A consensus on the use of oral prostacyclin pathway agents (PPAs), like Uptravi (selexipag), as an add-on to…
Articles by Joana Carvalho, PhD
An international consensus is lacking about what constitutes pulmonary hypertension (PH) in newborns, according to a review study, which…
Tikosyn (dofetilide), a medicine approved by the U.S. Food and Drug Administration (FDA) to treat heart…
Bioelectronic medicine is a promising new therapeutic approach to treat pulmonary arterial hypertension (PAH), according to a recent review…
An antibody that recognizes and blocks the activity of osteoprotegerin, a protein involved in the development of pulmonary…
Higher levels of a protein involved in certain immune responses, called soluble suppression of tumorigenicity-2 (sST2), are associated with more severe…
The Endoarterial Biopsy Catheter (EABC), a tool for performing biopsies on lung artery walls to better evaluate pulmonary…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to SoniVie’s Therapeutic…
Swedish men and women who have been diagnosed with idiopathic pulmonary arterial hypertension (IPAH) in recent years have similar survival…
Lung inflammation caused by a seemingly treatable and common infection may drive the onset of pulmonary arterial hypertension (PAH)…
A combination therapy of endothelin receptor antagonists (ERA) plus phosphodiesterase-5 inhibitors (PDE5i) — two different agents that induce…
People who were born prematurely, especially in recent years, are more likely to develop pulmonary arterial hypertension (PAH) later…